A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Adult Patients with Moderate to Severe Atopic Dermatitis
Latest Information Update: 19 Feb 2025
At a glance
- Drugs VC 005 (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Vcare Pharmatech
Most Recent Events
- 11 Feb 2025 Status changed from not yet recruiting to recruiting.
- 11 Dec 2024 New trial record